Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease
Julio A. Lamprea‐Montealegre, Erin Madden, Sri Lekha Tummalapalli, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 2900-2906
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 91
Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease
Chi D. Chu, Fang Xia, Yuxian Du, et al.
JAMA Network Open (2023) Vol. 6, Iss. 7, pp. e2326230-e2326230
Open Access | Times Cited: 49
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Zachary L. Cox, Sean P. Collins, Gabriel A. Hernandez, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 14, pp. 1295-1306
Closed Access | Times Cited: 42
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Ellen M. Apperloo, Brendon L. Neuen, Robert A. Fletcher, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 8, pp. 545-557
Open Access | Times Cited: 37
International consensus on post-transplantation diabetes mellitus
Adnan Sharif, Harini A. Chakkera, Aiko P. J. de Vries, et al.
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 3, pp. 531-549
Open Access | Times Cited: 24
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020
Susanne B. Nicholas, Kenn B. Daratha, Radica Z. Alicic, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2970-2979
Open Access | Times Cited: 33
Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study
Anna Forbes, William Hinton, Michael Feher, et al.
EClinicalMedicine (2024) Vol. 68, pp. 102426-102426
Open Access | Times Cited: 13
Cardiovascular-Kidney-Metabolic Health Syndrome
Nisha Bansal, Daniel E. Weiner, Mark J. Sarnak
Journal of the American Society of Nephrology (2024) Vol. 35, Iss. 5, pp. 649-652
Open Access | Times Cited: 5
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes
Daniel Edmonston, Elizabeth Lydon, Hillary Mulder, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2418808-e2418808
Open Access | Times Cited: 5
Decision Aids in Kidney Care: The Need for Interventions Addressing Kidney Disease in Marginalized Populations
Delphine S. Tuot, Lilia Cervantes
American Journal of Kidney Diseases (2025)
Closed Access
Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors
Kellye Eagan, Charlotte Bolch, Elizabeth Van Dril, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Closed Access
Study of the prescription pattern of antidiabetics in hypertension with diabetes patients in geriatric population at tertiary care centre: a retrospective observational study
Aparna Pal, Mirza S. Baig, Shailaja V Rao
International Journal of Research in Medical Sciences (2025) Vol. 13, Iss. 3, pp. 1051-1058
Open Access
Guideline-directed medical therapies (GDMTs) for chronic kidney disease with type 2 diabetes (CKD + T2D): Translation of lessons learned from the management of heart failure
Jonathan Rollins, Alison Hong, Bridgette Kanz Schroader, et al.
Journal of Diabetes and its Complications (2025) Vol. 39, Iss. 4, pp. 108985-108985
Closed Access
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence
Josiah Moore, Ndidi Iheme, Nicholas Rebold, et al.
Pharmacy (2025) Vol. 13, Iss. 2, pp. 46-46
Open Access
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study
Manel Pladevall, Ryan Ziemiecki, Catherine B. Johannes, et al.
Diabetes Therapy (2025)
Open Access
Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data
Brendon L. Neuen, Min Jun, James Wick, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 43, pp. 100988-100988
Open Access | Times Cited: 12
Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease
Christine P. Limonte, Julio A. Lamprea‐Montealegre, Katherine R. Tuttle
Seminars in Nephrology (2024) Vol. 44, Iss. 2, pp. 151520-151520
Closed Access | Times Cited: 2
Racial and Ethnic Disparities and Facility-Level Variation in GLP-1 RA Prescription among US Veterans with CKD
L. Parker Gregg, Melandrea L. Worsley, David J. Ramsey, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 11, pp. 1479-1482
Closed Access | Times Cited: 5
The 2022 American Diabetes Association Meeting
Zachary T. Bloomgarden
Journal of Diabetes (2022) Vol. 14, Iss. 7, pp. 428-433
Open Access | Times Cited: 8
Unlocking the potential: boosting SGLT2 inhibitor uptake to prevent the cardiorenal consequences of chronic kidney disease
Julio A. Lamprea‐Montealegre
The Lancet Regional Health - Western Pacific (2024) Vol. 43, pp. 101004-101004
Open Access | Times Cited: 1
Beyond clinical practice guidelines: The risk-treatment paradox in frail older adults
Liang‐Kung Chen
Archives of Gerontology and Geriatrics (2024) Vol. 119, pp. 105369-105369
Closed Access | Times Cited: 1
Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0301056-e0301056
Open Access | Times Cited: 1
Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care
Brendon L. Neuen, Min Jun, James Wick, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Long-term lessons from EMPA-KIDNEY
Lauren Heath, Carol A. Pollock
Nature Reviews Nephrology (2024)
Closed Access
Toward Guideline-Directed Medical Therapy in Nephrology
Evan Zeitler, Amy K. Mottl
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 12, pp. 1710-1712
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top